MSAC - Meeting 22-23 November 2018

Medical Services Advisory Committee - Applications Considered

• 1357.1 - F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer
• 1405.1 - MBS Item Number for Pulmonary Rehabilitation
• 1407 - EGFR mutation testing to determine eligibility for access to PBS subsidised osimertinib second line therapy in patients with locally advanced or metastatic NSCLC
• 1455 - Proton Beam Therapy for patients supported under the Medical Treatment Overseas Program
• 1456 - 17p Deletion Testing for Access to Venetoclax in Patients with Relapsed/Refractory Chronic Lymphoid Leukaemia
• 1466 - Vertebroplasty for severely painful osteoporotic vertebral fractures of less than 6 weeks duration
• 1498 - Serum Soluble Transferrin receptor
• 1510 - Emicizumab for routine prophylaxis, to prevent bleeding or reduce frequency of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency), with factor VIII inhibitors
• 1519 - Tisagenlecleucel (CTL019 - CAR-T therapy) for treatment of refractory CD19-positive leukaemia and lymphoma
• 1530 - Purified human alpha1-proteinase inhibitor (A1-P1) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD)
• 1541 - Micro-bypass glaucoma surgery (MBGS) device implantation as a standalone procedure in patients with open-angle glaucoma
• 1543 - Request to amend Medicare Benefits Schedule (MBS) item 73336 (BRAF mutation test for treatment of metastatic melanoma) to include reference to encorafenib